- RiverVest Venture Partners, a St. Louis-based venture capital firm, closed its RiverVest Venture Fund V, L.P., at $275m
- Fund V is RiverVest’s largest fund to date, with commitments from a wide range of institutional investors, as well as family offices and individual investors
- The vehicle brings the firm’s total assets under management to more than $1.6 billion
- RiverVest invests in early-stage biopharma and medical device companies addressing significant unmet medical needs
- Today, there are at least 27 commercial products treating patients and many in development from companies in which RiverVest has invested
- They include drugs such as Lokelma, a treatment for hyperkalemia, a life-threatening condition caused by elevated potassium levels, developed by ZS Pharma and commercialized by AstraZeneca in 2018
